Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB

Dian-cai ZHANG, Jin-long LIU, Yong-bin DING, Jian-guo XIA*, Guo-yu CHEN*

Department of General Surgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China

Aim: Gemcitabine has been increasingly prescribed for the treatment of gallbladder cancer. However, the response rate is low. The aim of this study is to determine whether icariin, a flavonoid isolated from *Epimedi herba*, could potentiate the antitumor activity of gemcitabine in gallbladder cancer.

Methods: Human gallbladder carcinoma cell lines GBC-SD and SGC-996 were tested. Cell proliferation and apoptosis were analyzed using MTT assay and flow cytometry, respectively. The expression of apoptosis- and proliferation-related molecules was detected with Western blotting. Caspase-3 activity was analyzed using colorimetric assay, and NF-κB activity was measured with ELISA. A gallbladder cancer xenograft model was established in female BALB/c (nu/nu) mice. The mice were intraperitoneally administered gemcitabine (125 mg/kg) in combination with icariin (40 mg/kg) for 2 weeks.

Results: Icariin (40–160 µg/mL) dose-dependently suppressed cell proliferation and induced apoptosis in both GBC-SD and SGC-996 cells, with SGC-996 cells being less sensitive to the drug. Icariin (40 µg/mL) significantly enhanced the antitumor activity of gemcitabine (0.5 µmol/L) in both GBC-SD and SGC-996 cells. The mice bearing gallbladder cancer xenograft treated with gemcitabine in combination with icariin exhibited significantly smaller tumor size than the mice treated with either drug alone. In GBC-SD cells, icariin significantly inhibited both the constitutive and gemcitabine-induced NF-κB activity, enhanced caspase-3 activity, induced G0-G1 phase arrest, and suppressed the expression of Bcl-2, Bcl-xL and surviving proteins.

Conclusion: Icariin, by suppressing NF-κB activity, exerts antitumor activity, and potentiates the antitumor activity of gemcitabine in gallbladder cancer. Combined administration of gemcitabine and icariin may offer a better therapeutic option for the patients with gallbladder cancer.

Keywords: gallbladder cancer; GBC-SD cell; SGC-996 cell; cancer xenograft model; icariin; gemcitabine; NF-κB; cell cycle arrest; apoptosis; synergistic effect
vitro in mouse Leydig tumor cells, human lung cancer cells, human gastric cancer cells, human leukemia cells, human breast cancer cells and human hepatoma cells. Although Icariin does not have sufficient potency to be used as a single-agent anticancer drug, these studies suggested that combinational therapy with Icariin and conventional chemotherapeutics might provide a treatment option with higher clinical efficacy and better patient survival.

In the present study, our results showed that icariin exhibited antiproliferative and proapoptotic effects on gallbladder cancer cells. We also found that icariin sensitized gallbladder cancer cells to gemcitabine, enhancing gemcitabine-induced growth inhibition and apoptosis. Moreover, we also examined the anticancer activity of icariin in combination with gemcitabine in a murine gallbladder cancer model and found that icariin treatment potentiated the cytotoxicity of gemcitabine in vivo. This synergistic anticancer activity is associated with the downregulation of NF-kB activity and apoptosis-related molecules (Bcl-2, Bcl-xL, and survivin).

Materials and methods

Cell culture

The human gallbladder carcinoma cell lines GBC-SD and SGC-996 were obtained from the Shanghai Cell Institute Country Cell Bank. Normal murine gallbladder cells were prepared as previously described. All cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Life Sciences, Carlsbad, CA, USA) containing 10% fetal bovine serum, 100 units/mL penicillin and 100 µg/mL streptomycin. Cells were maintained in a humidified incubator at 37°C and 5% CO₂.

Cell growth assay

Cell proliferation was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT) (Sigma, St Louis, MO, USA), as previously described. Briefly, cells were plated at a density of 5×10⁴ cells/well in 96-well culture plates. After treatment, 20 µL of MTT solution [5 mg/mL in phosphate-buffered saline (PBS)] was added to each well and incubated for 2 h. MTT formazan was dissolved in 150 µL of isopropanol, and the absorbance was measured at 595 nm with an ELISA reader (Tecan Group Ltd, Männedorf, Switzerland).

Cell apoptosis analysis

Cell apoptosis was determined using a FITC Annexin V apoptosis kit (BD Pharmingen, Franklin Lakes, NJ, USA) according to the manufacturer’s instructions. In brief, cells were washed with ice-cold PBS and resuspended in binding buffer (10 mmol/L HEPES, pH 7.4, 140 mmol/L NaCl, and 2.5 mmol/L CaCl₂) at a concentration of 1×10⁵ cells/mL. Cells were stained with annexin V-FITC and propidium (PI) for 15 min in the dark before analysis by a flow cytometer (Beckman Coulter Inc, Miami, FL, USA).

Western blot analysis

Following treatment, cells were washed with ice-cold PBS and harvested in 100 µL of cell lysis buffer (Cell Signaling, Danvers, MA, USA) containing protease inhibitors (Sigma, St Louis, MO, USA). Extracted proteins were separated by SDS-PAGE and then transferred electrophoretically onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Proteins were probed with specific antibodies as previously described.

Caspase-3 activity

Caspase-3 activity was measured in the cell lysate by a colorimetric assay according to the manufacturer’s instructions (Keygen Biotech, Nanjing, China). Briefly, 1×10⁶ cells were extensively washed with PBS and resuspended in 50 µL lysis buffer before incubation in an ice bath for 60 min. The solution was then centrifuged at 10000×g for 1 minute. The supernatant was collected and incubated with an enzyme-specific colorimetric substrate for 4 h at 37°C, and the colorimetric product was measured by an ELISA reader at a wavelength of 405 nm.

Analysis of cell cycle

The cell cycle was analyzed as previously described. Following treatment, cells were collected and fixed with 70% cold ethanol at 4°C overnight. DNA was stained with propidium iodide (0.05 mg/mL) and RNase (2 mg/mL) for 30 min at room temperature. A FACScan flow cytometer (Beckman Coulter Inc, Miami, Florida, USA) was used to analyze cells, and the percentage of cells in the G₀/G₁, S, and G₂/M phases of the cell cycle was assessed with Cell Lab Quanta SC Software.

NF-κB p65 activity analysis

Following treatment, the nuclear extract was prepared using a nuclear extract kit (Active Motif, Carlsbad, CA, USA), and the activity of NF-κB p65 was examined using an ELISA kit (Active Motif, Carlsbad, CA, USA).

In vivo xenograft experiments

The animal experiments were performed in accordance with CAPN (China Animal Protection Law), and the protocols were approved by the Animal Care and Use Committee of the First Affiliated Hospital, Nanjing Medical University. Female BALB/c (nu/nu) mice, 6 weeks old, purchased from theAnimal Centre of China (Beijing, China), were housed with a light/dark cycle of 12/12 h and allowed free access to rodent chow and water. GBC-SD cells were harvested from subconfluent cultures and washed in serum-free medium before being resuspended in PBS. The mice were anesthetized using ethyl ether, and 10⁵ cells were injected subcutaneously into the right and left abdominal regions with a gauge needle. Tumor appearance was inspected twice per week. Once tumor masses became established and palpable, animals were randomized into 4 groups (n=15 per group) to receive intraperitoneal injections as follows: (A) vehicle (0.9% sodium chloride plus 1% DMSO) (B) Icariin (40 mg/kg, dissolved in vehicle) alone, (C) gemcitabine (125 mg/kg, dissolved in vehicle) alone, and (D) Icariin (40 mg/kg, dissolved in vehicle) plus gemcitabine (125 mg/kg, dissolved in vehicle) together.
Vehicle (14) alone, or (D) Icariin and gemcitabine in combination twice per week for 2 weeks. Tumor volumes and body weight were measured twice per week. Tumor volume was measured along the longest orthogonal axes and calculated as volume = (length × width × height) / 2, where width was the shortest measurement. All mice were sacrificed 35 d after the first day of treatment.

Statistical analysis
All data are expressed as the mean ± SD and represent the results of three separate experiments performed in quadruplicate unless otherwise stated. Student’s t-test was used to evaluate the difference between two groups, and a one-way ANOVA with a post hoc test was used for comparison among three or more groups. *P* < 0.05 was considered to be statistically significant.

Results

Icariin inhibits cell growth and induces apoptosis in gallbladder cancer cells

To determine whether icariin could inhibit the growth of gallbladder cancer cells, the viability of the cells was assessed using the MTT assay after the cells had been treated with increasing concentrations of icariin for 24 h. As shown in Figure 1A and 1B, icariin inhibited GBC-SD cell growth in a dose-dependent manner. Relative to the control, GBC-SD cell viability was reduced up to 27.1% ± 2.2% after 160 μg/mL icariin treatment for 24 h. SGC996 cells were less sensitive to icariin than GBC-SD cells, showing a reduced viability of 35.5% ± 3.7% after 160 μg/mL icariin treatment for 24 h. We also evaluated the ability of icariin to induce apoptosis in GBC-SD and SGC996 cells. As shown in Figure 1A and 1B, icariin effectively induced apoptosis in both cell lines, indicating that the loss of cell viability in response to icariin was in part due to apoptosis. In contrast, even at the maximum dose tested, icariin did not significantly affect the viability of normal mouse gallbladder cells.

Icariin inhibits antiapoptotic molecules in GBC-SD cells

To explore the mechanism underlying icariin-induced apoptosis, we carried out Western blot analysis on GBC-SD cells. As shown in Figure 2A and 2B, icariin treatment caused a decrease in the level of caspase-3 and an increase in the PARP level while elevating caspase-3 activity, further confirming that the antiproliferative activity of icariin was mediated by inducing apoptosis. Our results also revealed that icariin decreased the levels of the antiapoptotic proteins Bcl-2, Bcl-xL, and survivin in a dose-dependent manner, suggesting that icariin induced apoptosis at least partially by inhibiting antiapoptotic molecules.

Icariin inhibits activation of NF-κB

The NF-κB signaling pathway plays a crucial role in cancer cell survival and is known to regulate the expression of survivin and Bcl family molecules (15). Therefore, we examined NF-κB activity in GBC-SD cells to investigate the effect of icariin on NF-κB activity. Icariin treatment led to a dose-dependent decrease in NF-κB activity as shown in Figure 2C, indicating that icariin downregulated antiapoptotic molecules by inhibiting NF-κB activity.

Icariin sensitizes gallbladder cancer cells to gemcitabine

To explore whether icariin could enhance the chemosensitivity of gallbladder cancer cells to gemcitabine, we examined the effect of treatment with gemcitabine alone or in combination with icariin on the growth of GBC-SD and SGC996 cells. Because icariin at 40 μg/mL had no effect on normal mouse gallbladder cells and significantly inhibited cell growth in both tested cell lines, we used 40 μg/mL icariin in the combinational treatment with gemcitabine. As shown in Figure 3A, treatment with either gemcitabine or icariin alone caused a 42% and 47% loss of viable GBC-SD cells, respectively. However, combination treatment with gemcitabine and icariin dramatically reduced the viable GBC-SD cells to 28%. A similar pattern was found in SGC-996 cells when the cells were treated with gemcitabine, icariin or both. To evaluate this synergism, we calculated the combination index value according to Chou’s method (16). The results showed that icariin caused a synergistic loss of cell viability when combined with gemcitabine (CI = 0.694 and 0.712 for GBC-SD and SGC-996 cells, respectively).

Icariin sensitized GBC-SD and SGC996 cells to apoptosis induced by gemcitabine

Next, we examined whether the enhanced antiproliferative effect was mediated by apoptosis. Compared with treatment with gemcitabine alone, combination treatment with icariin and gemcitabine induced significantly more apoptosis in both tested gallbladder cancer cell lines, indicating that icariin potentiates the cytotoxic effect of gemcitabine by inducing apoptosis (Figure 3B).

Icariin enhanced gemcitabine-induced apoptosis by regulating NF-κB and its downstream genes

The mechanism by which icariin sensitized gallbladder cancer cells was investigated using GBC-SD cells. Our results demonstrated that combinational therapy with icariin and gemcitabine caused additional inhibition of apoptosis-related molecules and a marked increase in caspase-3 activity that correlated with a dramatic inhibition in NF-κB activity (Figure 4A, 4B, and 4C). As shown in Figure 4C, icariin inhibited the constitutive action of NF-κB as well as gemcitabine-induced NF-κB activity. Combining these data with the initial findings, these results suggested that icariin sensitized cells to gemcitabine-induced apoptosis by inhibiting NF-κB activity and causing the ensuing downregulation of apoptosis-related genes.

Icariin potentiated gemcitabine-induced G0-G1 arrest

Untreated GBC-SD cells showed a similar cell cycle pattern, with most cells in S-phase and a lower proportion in the G0-G1 and G2 phases. Gemcitabine treatment alone increased G0-G1
cell cycle arrest relative to the control as shown in Figure 4D. Although icariin alone did change the cell cycle distribution, icariin and gemcitabine together resulted in an increased cell population arrested at G₀-G₁ phase. These results demonstrated that icariin treatment enhanced the cell cycle arrest caused by gemcitabine. Taken together, these in vitro results verified that icariin sensitizes gallbladder cancer cells to gemcitabine therapy and potentiates apoptosis by inhibiting NF-κB activity.

Icariin potentiates the in vivo antitumor effect of gemcitabine in GBC-SD and SGC996 cells

Based on the aforementioned results, we evaluated the in vivo therapeutic effect of icariin and gemcitabine treatment using an in vivo xenograft mouse model. Icariin was administered at 40 mg/kg, and gemcitabine was given at 125 mg/kg. Treatment started when the tumor size reached 0.5 cm³. The efficacy of the treatment was evaluated by measuring the tumor volume during treatment. As shown in Figure 5, treatment with icariin and gemcitabine resulted in significantly smaller
tumors than in control mice ($P<0.05$) or mice treated with gemcitabine or icariin alone ($P<0.05$).

**Discussion**
Owing to its late presentation and aggressive behavior, gall-bladder cancer remains one of the most malignant cancers, with an extremely low 5-year survival rate. In recent years, the actions of natural compounds that exert anti-cancer activity without harming normal cells have been widely investigated in diverse cancer cells. Combination treatment with natural
compounds has also received considerable attention because the synergistic interaction of several agents might decrease the systemic toxicity of chemotherapy by achieving the same efficacy with lower doses. However, only one natural compound has been reported to be able to potentiate the cytotoxic activity of platinum anticancer drugs in gallbladder cancer cells [17]. In this study, our results showed that icariin, by inhibiting NF-κB activity, exhibited antitumor activity and potentiated the anti-tumor activity of gemcitabine in gallbladder cancer.

It has been reported that icariin can regulate NF-κB activity in a variety of cell types [5]. Xu et al reported that icariin enhanced endothelial nitric oxide synthase expression in human endothelial cells and that this was correlated with an increase in NF-κB activity [18]. Icariin has also been reported to promote cardiac differentiation of mouse embryonic stem cells by activating NF-κB [19]. By contrast, icariin attenuated lipopolysaccharide-induced neuroinflammation, lung inflammation, osteoclast differentiation and bone resorption by suppressing NF-κB [20-23]. In the present study, we found that the inhibition of NF-κB activity by icariin led to apoptosis in gallbladder cancer cells, which have highly active NF-κB [23]. It seemed that the regulatory effect of icariin was cell specific and that icariin might only suppress NF-κB activity in cells with abnormally high NF-κB activity such as tumor cells or cells stimulated by external stimuli.

Emerging evidence has shown that NF-κB plays a crucial role in cell proliferation, invasion, apoptosis inhibition, chemoresistance and radioresistance [24]. Activation of NF-κB by several conventional chemotherapeutics has also resulted in unfavorable clinical outcomes. A number of studies have...
shown that the antitumor effect of gemcitabine was enhanced by inhibiting NF-κB. In pancreatic cancer cells, the efficacy of gemcitabine was found to be augmented when NF-κB activity was inhibited by escin, emodin, gum mastic, resveratrol or thymoquinone[24–28]. In addition to this finding for pancreatic cancer, enhanced chemosensitivity to gemcitabine has also been reported to be associated with decreased NF-κB activity in osteosarcoma, colon cancer, breast cancer, bladder cancer and non-small cell lung cancer cells[15, 29–31]. In agreement with these studies, we found that the sensitization of gallbladder cancer cells to gemcitabine by icariin correlated with suppressed NF-κB activity. Taken together, these results indicate that Therefore, the regulation of NF-κB activity could be a possible new treatment for the chemosensitization of human gallbladder cancer to gemcitabine. Furthermore, Wu et al also suggested that active NF-κB contributes to the highly invasive and metastatic behavior of gallbladder cancer[23]. Therefore, by suppressing NF-κB activity, icariin might be able to inhibit cell invasion, in addition to inducing apoptosis and suppressing cell growth.

To further understand how icariin sensitizes cells to gemcitabine, we examined cell cycle progression and the expression of the downstream genes of NF-κB. We found that icariin downregulated the constitutive expression of the apoptosis-related molecules Bcl-2, Bcl-xl, and survivin, and combination treatment showed a greater suppressive effect on these molecules. It has been suggested that survivin prevents the cell cycle through M phase and induces spontaneous apoptosis[25]. It is conceivable that the inhibition of survivin by icariin also contributes to the enhanced cytotoxicity of gemcitabine. In summary, our results indicated that icariin plays a synergistic role in gemcitabine-induced apoptosis and growth inhibition in gallbladder cancer cells.

To examine whether the enhanced cell growth inhibition and induction of apoptosis could be recapitulated in vivo, we treated a gallbladder cancer mouse model with icariin, gemcitabine or a combination of icariin and gemcitabine. Our results showed that the combination treatment led to a significant inhibition of tumor growth compared to treatment with either agent alone. More importantly, as shown in Figure 1C, icariin had a minimal effect on the viability of normal cells, so the combination of gemcitabine with icariin could achieve a greater therapeutic effect without causing systemic toxicity, a beneficial characteristic of combination therapy with two or more chemotherapeutics.

In conclusion, our results demonstrated that icariin can potentiate the antitumor activity of gemcitabine on human gallbladder cancer cells both in vitro and in vivo. The underlying mechanisms may be, at least in part, due to icariin-induced suppression of NF-κB and NF-κB-regulated gene products. Given the low toxicity of icariin to normal tissue and our present findings, we believe that icariin may also synergize with gemcitabine against other cancers such as pancreatic cancer. However, further studies, including preclinical studies and clinical trials, are needed to support our strategy for the treatment for gallbladder cancer.

Acknowledgements
This work was supported by grants from National Natural Science Foundation of China (No 30901443) and from the Opening Project of Medical Key Disciplines in Jiangsu Province (No XK03 200904).

Author contribution
Dian-cai ZHANG, Jian-guo XIA, and Guo-yu CHEN designed research; Dian-cai ZHANG and Jin-long LIU performed research; Dian-cai ZHANG and Yong-bin DING analyzed data; Dian-cai ZHANG and Jian-guo XIA wrote the paper.

References
1 Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 2007; 11: 671–81.
2 Kaneoka Y, Yamaguchi A, Isogai M, Harada T, Suzuki M. Hepatoduodenal ligament invasion by gallbladder carcinoma: histologic patterns and surgical recommendation. World J Surg 2003; 27: 260–5.
3 Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett 2009; 281: 71–81.
4 Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010; 15: 168–81.
5 Chen Y, Huang JH, Ning Y, Shen ZY. Icariin and its pharmaceutical efficacy: research progress of molecular mechanism. Zhong Xi Yi Jie He Xue Bao 2011; 9: 1179–84.
Huang X, Zhu D, Lou Y. A novel anticancer agent, icariin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol 2007; 564: 26–36.

Li S, Dong P, Wang J, Zhang J, Gu J, Wu X, et al. Icariin, a natural flavonoid glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Lett 2010; 298: 222–30.

Lin CC, Ng FF, Shieh DE, Chiang LC. Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukemia cell growth. Clin Exp Pharmacol Physiol 2004; 31: 65–9.

Wang Y, Dong H, Zhu M, Ou Y, Zhang J, Luo H, et al. Icariin exerts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated-phosphotrotein via Rac1 pathway. Eur J Pharmacol 2010; 635: 40–8.

Wang Q, Hao J, Pu J, Zhao L, Lu Z, Hu J, et al. Icariin induces apoptosis in mouse MLTC-10 Leydig tumor cells through activation of the mitochondrial pathway and down-regulation of the expression of p53. Int J Oncol 2011; 39: 973–80.

Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, et al. Icariin exterts sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol 2011; 67: 637–46.

Huang H, Chen D, Li S, Li X, Liu N, Lu X, et al. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett 2011; 301: 221–8.

Mita Y, Akiki T, Kamigaki T, Okazaki T, Hori H, Horiiuchi H, et al. Anti-tumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice. Ann Surg Oncol 2007; 14: 1374–80.

Guo X, Xu B, Pandey S, Goolgi E, Brown J, Armessilla AL, et al. Disulfiram/copper complex inhibiting NF-kappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett 2010; 290: 104–13.

Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.

Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi G, et al. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathione depletion and MR1P downregulation. Biochem Pharmacol 2010; 79: 1134–40.

Xu HB, Huang QZ. Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol 2007; 47: 18–24.